Provided by Tiger Trade Technology Pte. Ltd.

ZYMEWORKS INC (US)

29.41
+1.144.03%
Pre-market: 29.23-0.1812-0.62%08:18 EDT
Volume:716.49K
Turnover:20.92M
Market Cap:2.09B
PE:-14.56
High:29.70
Open:28.06
Low:27.81
Close:28.27
52wk High:30.62
52wk Low:13.60
Shares:70.96M
Float Shares:66.05M
Volume Ratio:0.68
T/O Rate:1.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0200
EPS(LYR):-1.0800
ROE:-72.31%
ROA:-24.14%
PB:25.97
PE(LYR):-27.23

Loading ...

Zymework’ partner Jazz to present on Ziihera at 2026 AACR Annual Meeting

TIPRANKS
·
Mar 18

Zymeworks partner Jazz to present four zanidatamab abstracts at AACR annual meeting

Reuters
·
Mar 18

Press Release: Zymeworks Announces Presentations for Ziihera(R) (zanidatamab-hrii) at 2026 AACR Annual Meeting

Dow Jones
·
Mar 18

Zymeworks to present ZW191 Phase 1 data and novel pan-RAS ADC platform at AACR Annual Meeting

Reuters
·
Mar 18

Analysts’ Top Healthcare Picks: GeneDx Holdings (WGS), Zymeworks (ZYME)

TIPRANKS
·
Mar 12

Zymeworks Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Mar 10

Zymeworks Earnings Call: Zanidatumab Drives Bullish Outlook

TIPRANKS
·
Mar 09

Zymeworks Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 06

Stock Track | Zymeworks Soars 5.45% Intraday on Positive Analyst Ratings and Price Target Increases

Stock Track
·
Mar 04

Zymeworks Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Mar 04

Truist Financial Keeps Their Buy Rating on Zymeworks (ZYME)

TIPRANKS
·
Mar 03

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Veeva Systems (VEEV), Zymeworks (ZYME) and Senseonics Holdings (SENS)

TIPRANKS
·
Mar 03

Stifel Nicolaus Reaffirms Their Buy Rating on Zymeworks (ZYME)

TIPRANKS
·
Mar 03

Zymeworks’ Growth Clouded by High Clinical Failure Risk and Regulatory Uncertainty

TIPRANKS
·
Mar 03

Zymeworks Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 02

Zymeworks Publishes Corporate Presentation on Royalty-Driven Growth Strategy and Oncology Pipeline Progress

Reuters
·
Mar 02

Zymeworks Q4 Net Loss Widens, Revenue Falls; Enters $250 Million Financing Agreement with Royalty Pharma

MT Newswires Live
·
Mar 02

Zymeworks, Royalty Pharma enter $250M royalty-backed note financing

TIPRANKS
·
Mar 02

Earnings Flash (ZYME) Zymeworks Posts Q4 Revenue $2.5M, vs. FactSet Est of $19.2M

MT Newswires Live
·
Mar 02

Zymeworks reports Q4 EPS (55c) vs. (31c) last year

TIPRANKS
·
Mar 02